Physician profile
John Anthony Nolan
NPI 1659329894
$1,580.68
in general payments reported to CMS, 2019-2025
19 companies · $317 in 2025
The $317 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $16.63 · 2021: $71.66 · 2022: $180 · 2023: $341 · 2024: $278 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $936.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $455.98 | 2021-2025 | |
| Edwards Lifesciences Corporation | $241.46 | 2019-2025 | |
| Pfizer INC. | $215.71 | 2019-2024 | |
| Abbott Laboratories | $137.25 | 2019 | |
| Medtronic Vascular, INC. | $86.90 | 2019 | |
| Boston Scientific Corporation | $83.79 | 2022-2024 | Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $75.35 | 2023-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.99 | 2023 | Jardiance |
| Kiniksa Pharmaceuticals, LTD. | $36.45 | 2023 | Arcalyst |
| Stryker Corporation | $34.12 | 2022 | |
| Merck Sharp & Dohme LLC | $28.80 | 2022 | |
| Lilly USA, LLC | $24.62 | 2025 | Zepbound |
| Astellas Pharma US INC | $24.00 | 2023 | Lexiscan |
| Amgen INC. | $20.36 | 2022 | |
| Novo Nordisk INC | $16.63 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $14.55 | 2023 | Inpefa |
| Bridgebio Pharma, INC. | $13.90 | 2025 | Attruby |
| Biohaven Pharmaceuticals, INC. | $13.62 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Nolan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.